![](https://ml.globenewswire.com/media/e9de96a4-582e-4975-8e43-6f3e6259c075/small/clene-logo-2x-png.png)
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from ...
Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline (hazard ratio: 0.431, p=0.0002) Average of 28% NfL reduction observed in an NfL responder subset (geometric …